This is a national observational retrospective multi-site chart review study of patients with advanced, recurrent or metastatic endometrial carcinoma.
Study Type
OBSERVATIONAL
Enrollment
200
Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
Clinical, biological and treatment characteristics
Description of the data
Time frame: up to 3 years
Progession Free Survival real world (rwPFS)
From the date of initiation of the treatment in the corresponding line to the date of progression or death
Time frame: through study completion, an average of 1 year
Overall Survival (OS)
From the date of initiation of the treatment in the corresponding line to the date of death
Time frame: through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Centre Hospitalier Victor Dupouy
Argenteuil, France
Sainte-Catherine Institut du Cancer Avignon-Provence
Avignon, France
CHRU Besançon - Hôpital Jean Minjoz
Besançon, France
Guillaume BABIN
Bordeaux, France
Hôpital Morvan CHRU de Brest
Brest, France
Centre d'Oncologie et de Radiothérapie 37
Chambray-lès-Tours, France
Hôpital Louis Mourier
Colombes, France
Centre Hospitalier Intercommunal de Créteil
Créteil, France
CHU de Dijon
Dijon, France
Centre Georges François Leclerc
Dijon, France
...and 20 more locations